Latest Schedule 13G passive stakes

Fourthstone LLC and associated entities have updated their beneficial ownership filing for Meridian Corporation, reporting a combined stake of 4.53% in the company's common stock.

Glenview Capital Management and Larry Robbins have filed an amended Schedule 13G, reporting no beneficial ownership of Myriad Genetics Inc. common stock as of June 30, 2026.

Glenview Capital Management, LLC and Larry Robbins have filed an amendment to their Schedule 13G, reporting no beneficial ownership of DXC Technology Co. common stock as of June 30, 2026.

Glenview Capital Management and Larry Robbins have reported a complete divestment of their holdings in ZoomInfo Technologies Inc. as of June 30, 2026.

Global X Management Company LLC has reported a beneficial ownership of 6.25% in Insteel Industries Inc., holding 1,209,588 shares as of June 30, 2026.

Global X Management Company LLC has disclosed a beneficial ownership of 6.32% in Genesis Energy LP's common units, holding 7,722,608 units.

Caracola Ventures Corp. has filed a Schedule 13G, revealing beneficial ownership of 9,000,000 shares, representing 8.9% of New ERA Energy & Digital, Inc.'s outstanding common stock.

ADAR1 Capital Management, LLC, along with related entities and Daniel Schneeberger, have updated their beneficial ownership filings for Freenome, Inc., reporting a combined 8.3% stake as of June 30, 2026.

WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. have updated their Schedule 13G filing regarding their beneficial ownership of Adagene Inc. ordinary shares.

Ares Partners Holdco LLC and Ares Acquisition Holdings III LP have jointly filed a Schedule 13G, disclosing a significant beneficial ownership of Ares Acquisition Corporation III's Class A ordinary shares.

A Schedule 13G filing reveals OLP Capital Management Ltd, Richard Li, and Di Fan Shen collectively beneficially own 11.42% of HUYA Inc.'s Class A ordinary shares as of June 30, 2026.

ADAR1 Capital Management and Daniel Schneeberger have updated their beneficial ownership filing for Spruce Biosciences, Inc., reporting a 2.5% stake as of June 30, 2026.

Several Venrock-affiliated entities have collectively reported beneficial ownership of 9.9% of VOR Biopharma's common stock as of June 30, 2026, due to a beneficial ownership blocker.

Split Rock Partners and associated entities have filed a Schedule 13G, reporting beneficial ownership of 2,937,570 shares of EBR Systems, Inc. common stock, representing 3.9% of the outstanding shares.

Venrock Healthcare Capital Partners III, L.P. and affiliated entities report a beneficial ownership of 4.7% of Tenax Therapeutics, Inc. common stock, primarily through warrants.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, have jointly filed an amendment to Schedule 13G, reporting a combined beneficial ownership of 98,101,407 shares of LifeStance Health Group, Inc. common stock, representing 25.7% of the outstanding shares.

Fourthstone LLC and associated entities have filed an amendment to their Schedule 13G, reporting changes in beneficial ownership of Parke Bankcorp, Inc. common stock.

Several Venrock-affiliated entities and individuals have reported a combined beneficial ownership of 7.4% in Oruka Therapeutics, Inc. common stock as of June 30, 2026.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filings for MainStreet Bancshares, Inc., reporting a combined holding of 0.67% of the company's common stock as of June 30, 2026.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filings for Investar Holding Corp, reporting a combined 2.34% stake.

Samsara BioCapital entities and Srinivas Akkaraju have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Eloxx Pharmaceuticals' common stock.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filing for Hanover Bancorp, Inc., reporting a combined 2.02% stake.

Several Fourthstone-affiliated entities have filed a Schedule 13G, reporting 0.00% beneficial ownership of First National Corporation's common stock.

Caligan Partners LP and David Johnson have reported beneficial ownership of 7,967,207 shares, representing 8.8% of SAB Biotherapeutics, Inc. common stock.

KalVista Pharmaceuticals, Inc. has filed an amendment to its Schedule 13G, reporting on beneficial ownership as of June 30, 2026.

Fourthstone LLC and affiliated entities report a passive ownership stake in FVCBankcorp, Inc. as of June 30, 2026.

Investment firm Two Seas Capital LP, along with its GP and chief investment officer Sina Toussi, has reported beneficial ownership of 7.5% of Calumet, Inc.'s common stock as of June 30, 2026.

CH4 Natural Solutions Acquisition Sponsor LLC and related entities report beneficial ownership of 7,333,334 Class B ordinary shares, convertible to Class A, representing 24.8% of the outstanding shares as of August 14, 2026.

Helen of Troy Limited has filed an amendment to its Schedule 13G, detailing changes in beneficial ownership of its common stock.

A group of investment entities, including Venrock Healthcare Capital Partners, has reported a combined beneficial ownership of 8.3% in Jade Biosciences, Inc. as of June 30, 2026.